Metabotropic glutamate receptors as targets for novel antipsychotic treatments.


Journal Article (Review)

In recent years metabotropic glutamate receptors have emerged as key targets for the design of new antipsychotic medications for schizophrenia, in particular mGluR5 and mGluR2/3. These receptors exhibit diverse interactions with other neurotransmitter receptors and critical elements of intracellular signalling cascades known to be important to the pharmacotherapy of schizophrenia. In addition, mGluR5 and mGluR2/3 are intimately involved in behavioural domains related to the symptoms of this disorder. Both animal and clinical studies using novel drugs targeting these receptors have provided encouraging results. The number of patents registered for drugs targeting metabotropic glutamate receptors has grown dramatically, and positive allosteric modulators for both receptors show particular promise.

Full Text

Duke Authors

Cited Authors

  • Gray, LJ; Hannan, AJ; Zhang, X

Published Date

  • June 2012

Published In

Volume / Issue

  • 13 / 8

Start / End Page

  • 1522 - 1534

PubMed ID

  • 22283756

Pubmed Central ID

  • 22283756

Electronic International Standard Serial Number (EISSN)

  • 1873-4316

Digital Object Identifier (DOI)

  • 10.2174/138920112800784817


  • eng

Conference Location

  • Netherlands